# Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

> **NCT00005960** · PHASE2 · UNKNOWN · sponsor: **Amgen**

## Conditions studied

- Pain
- Prostate Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** cyclophosphamide
- **DRUG:** docetaxel
- **DRUG:** doxorubicin hydrochloride
- **PROCEDURE:** pain therapy

## Key facts

- **NCT ID:** NCT00005960
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005960, "Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00005960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*